1 April 2025
Cambridge Cognition Holdings plc
("Cambridge Cognition", the "Company" or the "Group")
Block Listing Return
The Company makes the following notification pursuant to AIM Rule 29 and Schedule Six of the AIM Rules for Companies, regarding its existing block listings:
| Name of applicant: |
Cambridge Cognition Holdings plc |
|||
| Name of scheme: |
Share Options |
|||
| Period of return: |
From: |
1 October 2024 |
To: |
31 March 2025 |
| Number and class of share(s) (amount of stock / debt securities) originally listed and the date of admission: |
1,000,000 ordinary shares of £0.01 each in the Company admitted to trading on 23 March 2023 |
|||
| Balance of unallotted securities under scheme(s) from previous return: |
466,316 ordinary shares |
|||
| Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): |
Nil |
|||
| Less: Number of securities issued/allotted under scheme(s) during period: |
Nil |
|||
| Equals: Balance under scheme(s) not yet issued/allotted at end of period: |
466,316 ordinary shares |
|||
| Name of contact: |
Simon McKeating |
| Telephone number of contact: |
+44 (0)1223 810700 |
Enquiries:
|
Notes to Editors
About Cambridge Cognition
Cambridge Cognition is a brain health software group specializing in digital health products that advance brain health research and treatment.
The company offers four core products: CANTAB® assessments-providing scientifically validated, highly sensitive, precise, and objective measures of cognitive function correlated to neural networks; a flexible and proven eCOA platform with an extensive library of instruments, enabling efficient study setup and scalable data capture; rater training services that standardise assessment delivery and scoring across clinical trials and quality assurance tools that ensure data integrity by automatically detecting deviations in administration and scoring, saving time and money. These products collectively improve clinical trial outcomes, enable early patient identification, and enhance global efficiency in healthcare and pharmaceuticals.
For further information, visit: www.cambridgecognition.com